



ASX/MEDIA RELEASE

MANAGEMENT CHANGES

SYDNEY 29 SEPTEMBER, 2015 – Manufacturer and distributor of orthopaedic devices, Allegra Orthopaedics Limited (Allegra Orthopaedics) (ASX: AMT), advises that the Company's Chief Executive Officer and Chief Financial Officer, Tom Milicevic, has tendered his resignation that has been agreed will become effective on 9 October 2015.

Allegra Orthopaedics proposes to undertake a management restructure that reflects the size of its business and it is envisaged that this change will be effected over the next six months.

In the meantime, the Chief Executive Officer's role will be subsumed under the role of Managing Director with Peter Welsh remaining in the expanded role.

In addition, a consultant has been engaged to support Allegra Orthopaedics' existing financial and accounting resources.

Contact Details:

Mr Peter Welsh – Managing Director
Allegra Orthopaedics
T: 61 2 9439 4448

ABOUT ALLEGRA ORTHOPAEDICS

Allegra Orthopaedics is Australia's largest manufacturer of orthopaedic devices. Our focus is to deliver responsive customer service through our extensive capabilities. Our goal is to build a strong and profitable medical company.

Our principal product is the Active Total Knee, which has significantly improved the quality of life for people globally.

We also exclusively distribute ArthroSurface, Inc range of implantable orthopaedic devices.

Allegra Orthopaedics is the global licensee to a composite biocompatible ceramic material known as Sr-HT-Gahnite from The University of Sydney for veterinary and orthopaedic solutions. In preliminary studies, Sr-HT-Gahnite has duplicated the mechanical strength, elasticity and bioactivity of bone. Importantly, it is 100 times mechanically stronger than synthetic bone substitute materials in clinical use.

The company continues to build upon its extensive patent and product development portfolio. We have extensive research relationships with universities, companies and surgeon inventors. Our partnerships are building innovative products which will deliver significant shareholder wealth.